Document Detail


Who and how to treat with non-surgical myocardial reduction therapy in hypertrophic cardiomyopathy: long-term outcomes.
MedLine Citation:
PMID:  12634884     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Iatrogenic infarction of the hypertrophic intraventricular septum in hypertrophic obstructive cardiomyopathy has become an accepted treatment for patients refractory to medical treatment and/or pacemaker therapy. During the 8 years of its existence, non-surgical myocardial reduction (NSMR), which is based on the injection of absolute alcohol into the first or second septal perforator originating from the left anterior descending coronary artery, has been used more frequently than surgical myectomy. The advantages of this catheter procedure are local anesthesia, short hospital stay, and less morbidity as compared with open heart surgery. Patients with an interventricular septal thickness of at least 18 mm, left ventricular outflow tract gradient at rest of at least 30 mmHg, and an intraventricular gradient during provocation (such as isoproterenol, dobutamine, amylnitrate, and postextrasystolic potentiation) are potential candidates for this procedure. Important mitral valve abnormalities must be excluded prior to septal ablation with alcohol. In some patients, the coronary anatomy is unsuitable for this procedure. Mid-to-long-term results have shown very significant intraventricular gradient reduction, symptom improvement, reduction in left ventricular filling pressure and pulmonary artery pressure, and increase in exercise capacity. Complications, such as the need for long-term pacing, have fallen with the reduction of the total amount of injected alcohol and the use of contrast echocardiography. NSMR appears to be effective, and can be used as an alternative to classical surgical myectomy in symptomatic patients resistant to conservative treatment.
Authors:
Winston A Martin; Ulrich Sigwart
Related Documents :
18515784 - Ceramide is a cardiotoxin in lipotoxic cardiomyopathy.
20978574 - Reoperative myectomy via the left ventricular apex in a patient with hypertrophic obstr...
10921804 - Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international re...
10354194 - Cardiomyocyte apoptosis and progression of heart failure to transplantation.
9228544 - Effect of bradykinin b2-receptor antagonism on post-ischemic coronary reperfusion.
22069414 - Reviewing time intervals from onset of the symptoms to thrombolytic therapy in patients...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Heart failure monitor     Volume:  3     ISSN:  1470-8590     ISO Abbreviation:  Heart Fail Monit     Publication Date:  2002  
Date Detail:
Created Date:  2003-03-13     Completed Date:  2003-05-07     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  101140283     Medline TA:  Heart Fail Monit     Country:  England    
Other Details:
Languages:  eng     Pagination:  15-27     Citation Subset:  IM    
Affiliation:
Department of Cardiology, University Hospital of Geneva, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiomyopathy, Hypertrophic / radiography,  therapy*,  ultrasonography
Catheter Ablation / adverse effects,  contraindications,  methods*,  mortality
Follow-Up Studies
Humans
Patient Selection
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The impact of obesity on survival in patients with heart failure.
Next Document:  Antiarrhythmic therapy in heart failure.